FDA 483 - UF Reproductive Medicine at Springhill - June 06, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of UF Reproductive Medicine at Springhill in Gainesville, FL, a reproductive tissue establishment, identified significant deficiencies related to the processing and labeling of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Observations included inadequate labeling of HCT/Ps for which donor eligibility was not performed, specifically regarding warning statements for communicable disease risks. Additionally, the firm's procedures were found to be insufficient to ensure compliance with donor eligibility requirements, particularly concerning the use of biohazard legends for ineligible directed reproductive donors.
ID · c9046795-23ef-4ddc-871a-b5498b8d1bca